In ovarian cancer, SMAD1 positively regulates SOX2 and SMAD3 negatively regulates SOX2, which acts as a regulatory node that controls the signalling of the TGF-β pathway, which in turn affects ovarian cancer metastasis [123]. Here, SOX2 is linked to ovarian carcinoma.